Tisagenlecleucel in ALL: follow-up data and insights
Tisagenlecleucel (CTL019), a CAR T-cell agent, was approved for acute lymphoblastic leukemia (ALL) treatment in children and young adults last year after positive results from the ELIANA trial (NCT024...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Role of nivolumab maintenance in high-risk AML patients
Eunice Wang, MD, talks about the role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients<br />
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Transplant in ALL after CAR T-cells & amp; the role of MRD
With the recent influx of targeted, highly effective novel agents to the field of acute lymphoblastic leukemia (ALL), there is some uncertainty surrounding the role of aggressive treatments like stem ...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Evolving treatment considerations for FLT3 mutated AML
Eunice Wang, MD, talks about some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior TKI therapy at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
What we've learned about gilteritinib
Eunice Wang, MD, talks about what we've learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
BSH18_Chris Response to CAR T-cell treatment in CLL patients
Patients with advanced chronic lymphocytic leukemia (CLL) don't respond well to chimeric antigen receptor (CAR) T-cell therapy. In this interview, Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff Univ...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Response to CAR T-cell treatment in CLL patients
Patients with advanced chronic lymphocytic leukemia (CLL) don't respond well to chimeric antigen receptor (CAR) T-cell therapy. In this interview, Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff Univ...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Advancements in the use of MRD in AML in the UK: MyeChild01 and AML19
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia (AML). In this interview, Richard Dillon, MBBS, from King's College Lon...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The evolution of MRD-guided therapy for leukemia
Richard Dillon, MBBS, from King's College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timel...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Telomere length as a prognostic parameter in CLL
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia (CLL). In this interview, Chris Fegan, MB, MD, FRCP, FRCPa...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Physicians must perform molecular monitoing regularly for successful outcomes in CML
Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, talks about the TARGET survey, a survey of real-world management of chronic myeloid leukemia (CML) across 33 countries. This su...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Ibrutinib for CLL within a population-based setting: a promising outlook
To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather than a clinical trial setting, Lina van der Straten, Ph...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The potential impact of gilteritinib in patients with FLT3-ITD AML?
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with FLT3-ITD acute myeloid leukemia (AML)
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Evolving treatment considerations for FLT3 mutated AML
Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior FLT3 TKI therapy.
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Next-generation sequencing and treatment selection in AML
Eunice Wang, MD, talks about the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML) at ASCO 2018.
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
